
RealRate

PHARMACEUTICAL 2018

Orgenesis Inc. Rank 126 of 349







PHARMACEUTICAL 2018

Orgenesis Inc. Rank 126 of 349



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Orgenesis Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is -82%, being 196% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	7,295
Cost of Goods Sold	6,807
Intangible Assets	25,735
Liabilities, Current	16,914
Liabilities, Non-Current	5,229
Other Assets	1,738
Other Compr. Net Income	2,630
Other Expenses	321
Other Liabilities	0
Other Net Income	-3,661
Property and Equipment	5,104
Research and Development	2,478
Revenues	10,089
Selling, General and Administrative Expense	9,189

Output Variable	Value in 1000 USD
Assets	39,872
Liabilities	22,143
Expenses	18,795
Stockholders Equity	17,729
Net Income	-12,367
Comprehensive Net Income	-11,052
Economic Capital Ratio	-82%